INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases

Front

1 of 3 · Front

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease

INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases

In one breath

The INDEPSO-ISPSM consensus on colorectal peritoneal metastases, written for Indian epidemiology and access: cytoreductive surgery for selected isolated or resectable disease, adjuvant systemic chemotherapy after CRS, and HIPEC outside trials only selectively — particularly at PCI 11–15.

Edition2024

Issued byIndian Network for Development of Peritoneal Surface Oncology (INDEPSO) and Indian Society of Peritoneal Surface Malignancies (ISPSM)

Place of issueIndia

PublishedJCO Global Oncology · 2024;10

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers adults with colorectal peritoneal metastases, with explicit attention to Indian epidemiology, access, and sociodemographic context.

Applies to: Adults with colorectal peritoneal metastases, with explicit attention to Indian epidemiology, access, and sociodemographic context.

§2 · Key recommendations

CRS is recommended for selected isolated/resectable disease and can be considered with limited liver metastases.
The panel did not recommend changing the surgical approach solely for KRAS mutation.
Adjuvant systemic chemotherapy was recommended after CRS.
HIPEC outside trials was recommended only selectively, particularly PCI 11-15.
unresectable CPM should generally receive IPC only in clinical trials.
The document addresses work-up, systemic therapy integration, molecular profile, surveillance, and prevention.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

No formal evidence grading/rating was performed. Modified Delphi: 29 questions, 44 invited experts, consensus >70%, strong consensus >90%; 23/29 reached consensus.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Patel S, et al. INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases. JCO Glob Oncol. 2024;10. doi:10.1200/GO-24-00306.

Publisher — the record's original_url, carried verbatim ↗DOI — 10.1200/GO-24-00306 ↗

Link check 2026-11-11: the publisher URL returned HTTP 403 to automated fetching (publisher bot protection, not a dead link); carried verbatim per the record and marked publisher-fetch-blocked (spec §5.6). The DOI resolved at Crossref with matching title and journal instead.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #124, Domain 11) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Colorectal peritoneal metastases — PSOGI HIPEC consensus 2022 vs ESMO/North American guidance in the post-PRODIGE-7 era (this consensus is one of the post-PRODIGE-7 positions). Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div01-indepso-ispsm-colorectal-peritoneal-2024GS.code · Guidelines

More in Division 1 · Colorectal, Anorectal & Pilonidal Disease

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

EAES-SAGES Clinical Practice Guideline Update: Multi-Society Recommendations on Key Controversies in the Management of Diverticular Disease

A multi-society update on the key controversies in diverticular disease: no routine antibiotics for uncomplicated diverticulitis, elective resection for persistent symptoms after recurrent episodes or recovery from a first abscess, and no routine follow-up colonoscopy after a first uncomplicated episode.

2026 Update · European Association for Endoscopic Surgery (EAES) and SAGES, with AAST, CSSANZ, EAST, ESCP, UEG and WSES participation

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

The 2022 PSOGI consensus on HIPEC for colorectal peritoneal metastases: after complete cytoreductive surgery, HIPEC is conditionally recommended despite the negative PRODIGE-7 results — with short-duration high-dose oxaliplatin strongly rejected and mitomycin-C weakly favoured.

2022 Consensus · Peritoneal Surface Oncology Group International (PSOGI)

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results

The multi-society CRS/HIPEC guideline's methodology and overview paper: seven recommendations built by GRADE ADOLOPMENT — conditional for metachronous colorectal and gastric peritoneal metastases, strong for pseudomyxoma, peritoneal mesothelioma and advanced ovarian cancer after neoadjuvant chemotherapy.

2024 · PSOGI with the European Society of Surgical Oncology, ERN-EURACAN, the Society of Surgical Oncology and partner societies (14 countries)